Global Cardiac Biomarkers Market Size, Share, Trends & Growth Analysis Report Segmented By Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), Others), Application, Location of Testing And Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), 2026-2034

Cardiac Biomarkers Market Size Overview

The Cardiac Biomarkers Market size was valued at USD 5.44 Billion in 2025 and is projected to grow from USD 6.50 Billion in 2026 to USD 26.97 Billion by 2034, at a CAGR of 19.47% during the 2026-2034. North America dominated the cardiac biomarkers market with a market share of 42.88% in 2025.

The market is an essential segment within the global healthcare landscape, primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and advancements in diagnostic technologies. Cardiac biomarkers refer to biological substances found in the blood that are indicative of heart conditions. These biomarkers, such as troponins, natriuretic peptides, and creatine kinase, are critical in diagnosing and managing heart-related ailments, particularly in cases of acute myocardial infarction (heart attack), heart failure, and other cardiovascular disorders. As the global population ages, the burden of CVDs continues to escalate, pushing the demand for precise and timely diagnostics.

Recent statistics highlight the significant growth potential of the market. Factors such as the increasing incidence of heart diseases, the adoption of advanced diagnostic tools, and the shift towards personalized medicine are contributing to this growth trajectory. Furthermore, the expansion of healthcare infrastructure, particularly in emerging markets, is expected to further boost the demand for this market in both hospital settings and point-of-care testing. With the rise in awareness about cardiovascular health and improvements in biomarker technology, the market is poised for continued expansion.

Market Dynamics

Cardiac Biomarkers Market Drivers

• Rising Prevalence of Cardiovascular Diseases (CVDs): The increasing global burden of cardiovascular diseases is one of the primary drivers for the market. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death worldwide, accounting for approximately 31% of all global deaths. This alarming statistic emphasizes the demand for early diagnosis and management, with this market playing a crucial role in the early detection and monitoring of CVDs. The need for rapid, non-invasive diagnostic solutions, such as cardiac biomarkers, continues to rise in line with the growing number of patients affected by heart-related disorders. The rising incidence of heart disease in both developed and developing regions is fueling the growth of this market.
• Technological Advancements in Diagnostic Tools: Significant advancements in biomarker technologies and diagnostic devices are propelling the market forward. Newer, more accurate tests, such as high-sensitivity troponin assays, have revolutionized cardiac diagnostics. According to the U.S. Food and Drug Administration (FDA), the approval of high-sensitivity tests for troponin has enhanced the accuracy of diagnosing acute myocardial infarction, even in patients with minimal symptoms. These technological improvements in biomarker detection methods have led to better patient outcomes by enabling earlier detection, more precise risk stratification, and personalized treatment plans. The market continues to benefit from innovations in biomarkers that provide more reliable and faster results, further driving adoption in clinical and emergency care settings.
• Increasing Demand for Point-of-Care Diagnostics: The growing preference for point-of-care (POC) testing, especially in emergency care settings, is also fueling market growth. As per the U.S. Centers for Disease Control and Prevention (CDC), nearly 1 in 4 adults in the U.S. have some form of cardiovascular disease, creating a demand for faster diagnostic solutions. this market are crucial in POC diagnostics due to they offer rapid, reliable results that can help healthcare providers make quick, informed decisions. Point-of-care devices, like handheld devices and compact analyzers, allow healthcare professionals to perform immediate tests in emergency rooms, outpatient clinics, and ambulances. The increasing adoption of POC technologies in emerging markets is a major driver, expanding the reach of cardiac biomarker testing to under-resourced areas.
• Growing Awareness of Cardiovascular Health: Rising awareness regarding cardiovascular health and the importance of early detection is a significant driver for the market. Government agencies like the CDC have launched campaigns aimed at educating the public about the risks of heart disease, urging individuals to undergo regular screenings. This heightened awareness has led to an increase in demand for diagnostic tools that can detect cardiovascular conditions early, where biomarkers play a crucial role. The global awareness about heart health, driven by initiatives from the WHO and national health agencies, has also encouraged preventive healthcare measures, leading to an increased utilization of cardiac biomarker testing.
• Expansion of Healthcare Infrastructure in Emerging Markets: The growing healthcare infrastructure in emerging markets is another key driver of the market. According to the World Bank, emerging economies are seeing rapid advancements in healthcare systems, including the establishment of new hospitals, diagnostic centers, and clinics. This expansion has created a higher demand for diagnostic tools, particularly cardiac biomarkers, to address the rising number of cardiovascular cases. The affordability and accessibility of biomarkers in these regions have made them a popular choice for diagnosing heart diseases. As healthcare access improves, the adoption of this market for early detection and monitoring of heart conditions is expected to continue growing.

Cardiac Biomarkers Market Opportunities

• Growth in Personalized Medicine: The rise of personalized medicine presents a significant opportunity for the market. As treatments become more tailored to individual genetic and molecular profiles, cardiac biomarkers are playing a pivotal role in predicting responses to therapies. According to the U.S. National Institutes of Health (NIH), personalized medicine is expected to grow substantially, with an estimated market value of USD 3.68 billion by 2025. This shift towards customized healthcare provides a substantial opportunity for biomarkers to be integrated into therapeutic strategies, enabling more precise and effective management of cardiovascular diseases. The ability of biomarkers to predict patient-specific disease progression and treatment outcomes offers significant potential for their application in personalized cardiovascular care.
• Increase in Geriatric Population: The rapidly growing geriatric population is a major opportunity for the market. As per the World Health Organization (WHO), the global population aged 60 years and older is expected to double by 2050. This demographic shift is accompanied by an increased prevalence of chronic diseases, particularly cardiovascular conditions. Biomarkers play an essential role in diagnosing and managing heart diseases in older adults, who may exhibit atypical symptoms. This surge in the aging population is a prime opportunity for the market to grow, as healthcare systems will require more sophisticated diagnostic tools to address the cardiovascular needs of elderly individuals.
• Adoption of Artificial Intelligence (AI) in Diagnostics: The integration of artificial intelligence (AI) in diagnostic procedures presents a promising opportunity for the market. AI can enhance the analysis of biomarker data by improving the accuracy of readings, predicting disease progression, and aiding in faster decision-making. According to a report from the U.S. National Institute of Health (NIH), AI applications in healthcare diagnostics are expected to grow at a CAGR of 42% from 2020 to 2027. This technological advancement creates new avenues for cardiac biomarkers, offering the potential for more efficient, precise, and cost-effective diagnostics in clinical practice.
• Expansion in Emerging Markets: The expansion of healthcare access and infrastructure in emerging markets presents significant opportunities for the market. With increasing investments in healthcare by governments and private entities, countries such as India, China, and Brazil are experiencing rapid growth in medical diagnostics. The World Bank reports that healthcare spending in emerging markets is growing at a rate of over 6% annually. As access to healthcare improves in these regions, the demand for efficient and affordable cardiac diagnostics, including biomarkers, is expected to surge. This trend is expected to create new revenue streams and market growth opportunities in the coming years.
• Development of New Biomarkers for Early Detection: The continuous development of new and more sensitive biomarkers presents significant opportunities in this market. Researchers are constantly identifying novel biomarkers that can improve early detection and risk stratification for cardiovascular diseases. For instance, new biomarkers such as heart-type fatty acid-binding protein (H-FABP) and copeptin are being investigated for their potential in detecting heart disease at an earlier stage. The U.S. National Institutes of Health (NIH) is funding studies aimed at discovering and validating these new biomarkers, indicating a strong opportunity for expansion and innovation in the market. As the clinical validation of these biomarkers progresses, their integration into routine diagnostics could drive market growth.

Cardiac Biomarkers Market Restrain & Challenges

• High Cost of Advanced Testing: One of the significant challenges in this market is the high cost of advanced diagnostic tests and equipment. The implementation of cutting-edge technologies, such as high-sensitivity assays and multi-biomarker panels, often comes with a substantial price tag. According to the U.S. National Institutes of Health (NIH), the cost of some cardiac biomarker tests can limit their accessibility, particularly in low-resource settings or for uninsured patients. This financial barrier can hinder the widespread adoption of these tests, especially in emerging economies where healthcare budgets are constrained. The high cost is a critical challenge for both patients and healthcare systems, restricting the potential for more extensive use of this market in routine care.
• Lack of Standardization in Biomarker Testing: The absence of standardized testing methods across regions and healthcare systems is another major challenge. Different laboratories may use various assays or devices for detecting cardiac biomarkers, leading to variability in test results. According to the U.S. Food and Drug Administration (FDA), this lack of standardization can undermine the reliability of test results, resulting in inconsistencies in diagnosis and patient management. Additionally, variations in regulatory frameworks across countries complicate the global acceptance and integration of this market into routine clinical practice. This challenge impedes the widespread adoption of new biomarkers and hinders the ability of healthcare providers to make informed decisions consistently.
• Regulatory Hurdles for New Biomarkers: Regulatory approval processes for new cardiac biomarkers and diagnostic tests can be lengthy and complicated, limiting innovation in the market. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have stringent approval processes for medical devices and diagnostic tests, which can delay the introduction of potentially life-saving technologies. The rigorous clinical trials required for new biomarkers can take several years to complete, which is a significant barrier to the rapid deployment of novel diagnostics. As the regulatory landscape continues to evolve, delays in approval processes remain a critical challenge, especially for smaller companies or start-ups aiming to bring innovative biomarkers to market.
• Challenges in Early Diagnosis and Detection: While this market are essential in diagnosing cardiovascular diseases, their accuracy in early-stage detection remains a challenge. Not all biomarkers are effective in detecting cardiovascular conditions in asymptomatic or early-stage patients. According to the U.S. Centers for Disease Control and Prevention (CDC), many heart diseases develop silently, and biomarkers might not always detect these conditions in their nascent stages. Furthermore, overlapping symptoms with other conditions can complicate the interpretation of biomarker levels. As a result, there is an ongoing need for the development of more sensitive biomarkers that can identify cardiovascular conditions earlier and with greater specificity.
• Limited Awareness in Low-Resource Settings: In many low- and middle-income countries, there is limited awareness of the benefits and availability of this market for diagnosing heart diseases. According to the World Health Organization (WHO), cardiovascular diseases are responsible for 80% of deaths in low- and middle-income countries, yet access to diagnostics remains limited. The lack of healthcare infrastructure and awareness in these regions contributes to a low adoption rate of cardiac biomarkers for routine screening. Addressing this challenge requires both raising awareness and improving access to these diagnostic tools, which can significantly impact public health outcomes.

Current Trends in the Cardiac Biomarkers Market

• Integration of Artificial Intelligence in Cardiac Diagnostics: One of the most prominent trends in this market is the integration of artificial intelligence (AI) and machine learning (ML) algorithms in diagnostic tools. AI is being used to analyze complex biomarker data, improving diagnostic accuracy, and enabling early detection of cardiovascular conditions. The U.S. Food and Drug Administration (FDA) has approved several AI-based diagnostic devices for cardiovascular diseases, including those that analyze cardiac biomarkers. According to a report by the National Institutes of Health (NIH), the use of AI in cardiology is expected to grow by over 40% annually through 2027, revolutionizing the way heart diseases are diagnosed and monitored. This trend enables healthcare professionals to make faster and more accurate decisions, ultimately enhancing patient outcomes and reducing diagnostic errors.
• Point-of-Care (POC) Testing Advancements: Another significant trend is the growing adoption of point-of-care (POC) testing in cardiac biomarker diagnostics. POC testing allows for rapid, on-site diagnostic results, facilitating immediate clinical decisions, especially in emergency care settings. The Centers for Disease Control and Prevention (CDC) emphasizes the importance of fast, accessible diagnostics in reducing mortality rates from acute cardiovascular events such as heart attacks. The demand for POC testing is increasing in both developed and emerging markets, driven by the need for quicker diagnosis and improved patient management. The global POC diagnostics market is projected to reach USD 45 billion by 2025, with this market being a key focus area. The convenience, accuracy, and cost-effectiveness of POC tests are helping to drive this trend forward.
• Focus on Multi-Biomarker Panels: The trend of using multi-biomarker panels for more comprehensive cardiovascular risk assessment is gaining traction. These panels combine several biomarkers to provide a broader and more accurate picture of cardiovascular health. According to the National Heart, Lung, and Blood Institute (NHLBI), the use of multi-biomarker testing improves early diagnosis, risk stratification, and personalized treatment plans, especially for patients with multiple risk factors. Multi-biomarker panels are increasingly being used to diagnose conditions such as heart failure, myocardial infarction, and chronic kidney disease. This trend reflects the growing demand for more precise and individualized diagnostics, ensuring that patients receive the most appropriate treatments based on a broader understanding of their condition. The market for multi-biomarker panels is expected to expand significantly over the next decade.
• Emergence of Non-Invasive Biomarker Testing: Non-invasive biomarker testing is becoming a key trend in this market. Traditional cardiac biomarker tests often require blood samples or more invasive procedures, but new developments in non-invasive technologies, such as wearable sensors, are enabling real-time monitoring of biomarkers. The U.S. National Institutes of Health (NIH) is funding several studies aimed at developing non-invasive tests that can detect heart disease markers through sweat, saliva, or breath. These advancements make heart disease diagnostics less intrusive and more accessible, especially for continuous monitoring in high-risk patients. Non-invasive testing is expected to increase patient compliance and reduce the overall healthcare costs associated with traditional testing methods, driving the future growth of the market.
• Increased Focus on Personalized Cardiovascular Care: The growing emphasis on personalized medicine is influencing trends in cardiac biomarker development. Personalized medicine uses genetic, environmental, and lifestyle data to tailor treatments to individual patients. According to the U.S. National Institutes of Health (NIH), personalized medicine is expanding rapidly, with cardiovascular diseases being one of the key therapeutic areas. Biomarkers are critical in this approach, as they can help identify genetic predispositions to heart disease and determine the most effective treatment plans. The increasing adoption of precision medicine, driven by advances in genomics and biotechnology, is creating significant opportunities for the market, as patients demand more targeted and individualized care. This trend is expected to accelerate as healthcare systems worldwide adopt more patient-centered approaches.

Contact Us

Segmentation Insights

Cardiac Biomarkers Market Analysis, By Type

By Type, the market is divided into Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Others.

• Troponins, particularly Troponin T and Troponin I, represent the largest segment in the global market. This biomarker is widely considered the gold standard for diagnosing myocardial injury due to its high sensitivity and specificity for detecting acute myocardial infarction (AMI). According to the U.S. National Institutes of Health (NIH), troponin levels correlate closely with the severity of heart damage, making it crucial for accurate clinical decision-making. Troponins are highly valued in emergency settings, as they allow for rapid and reliable identification of heart attack victims, contributing to their dominance in the global market.
• The Brain Natriuretic Peptide (BNP) segment is the fastest-growing in this market. BNP and its precursor NT-proBNP are key indicators of heart failure, providing vital information regarding heart function and fluid balance. The segment's growth can be attributed to the increasing prevalence of heart failure worldwide, with the Centers for Disease Control and Prevention (CDC) reporting that approximately 6.2 million Americans are living with heart failure. BNP levels are essential for diagnosing and monitoring heart failure severity, making them invaluable for patient management. The expanding patient pool and advancements in diagnostic tools are accelerating the adoption of BNP testing, contributing to its rapid growth in the market.

Cardiac Biomarkers Market Analysis, By Application

By Application, the market is categorized into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others.

• The largest segment by application is Acute Coronary Syndrome (ACS). This segment's leading position is driven by the fact that cardiac biomarkers are a cornerstone of modern emergency medicine for patients presenting with chest pain or other symptoms suggestive of a heart attack. The use of highly sensitive troponin tests, in particular, has become standard practice for the rapid diagnosis, risk stratification, and rule-out of ACS, which includes myocardial infarction and unstable angina. The widespread and frequent testing for ACS in emergency departments globally solidifies this segment as the primary application for this market. The need for quick and accurate results to guide immediate and critical treatment decisions is a key factor sustaining its dominance.
• The fastest-growing segment is Congestive Heart Failure. The rapid increase in the global prevalence of heart failure, especially among the aging population, is a key driver for this growth. Biomarkers such as B-type natriuretic peptide (BNP) and NT-proBNP are increasingly used to aid in the diagnosis, severity assessment, and management of heart failure. These tests help clinicians differentiate heart failure from other causes of shortness of breath and guide treatment, making them an essential tool for chronic disease management. The rising focus on early detection and continuous monitoring of heart failure, along with the development of new, more sensitive biomarkers, is propelling this segment's growth. In this case, the largest segment (Acute Coronary Syndrome) and the fastest-growing segment (Congestive Heart Failure) are not the same.

Cardiac Biomarkers Market Analysis, By Location of Testing

By Location of Testing, the market is categorized into Point of Care Testing and Laboratory Testing.

• Laboratory testing is the largest segment in the global market. Laboratory tests, including those for Troponins and CK-MB, offer high accuracy and are widely used in diagnosing myocardial infarction and other cardiovascular conditions. The U.S. National Institutes of Health (NIH) emphasizes that laboratory-based tests are essential in clinical settings due to their reliability and comprehensive results. Laboratories provide specialized equipment and trained personnel, which ensures precise diagnostic outcomes. As cardiovascular diseases continue to be the leading cause of death globally, laboratory testing remains integral in the proper management and treatment of heart conditions, thus maintaining its dominance in the market.
• Point of care (POC) testing is the fastest-growing segment in this market. POC testing offers rapid results, enabling immediate clinical decisions, particularly in emergency settings. The Centers for Disease Control and Prevention (CDC) highlight that timely diagnosis is critical for reducing the mortality and morbidity associated with acute cardiac events. The demand for POC testing is rising due to its convenience, reduced turnaround time, and ability to be performed outside of traditional healthcare settings. With the increasing prevalence of heart disease, the market for POC cardiac biomarkers is expected to expand, offering more accessible and efficient diagnostic solutions.

Cardiac Biomarkers Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• North America is the largest region in the global market. The region’s dominance can be attributed to the high prevalence of cardiovascular diseases, coupled with advanced healthcare infrastructure and high adoption of diagnostic technologies. According to the Centers for Disease Control and Prevention (CDC), nearly 697,000 deaths in the United States were attributed to heart disease in 2020, making cardiovascular disease the leading cause of death in the country. The region also benefits from robust reimbursement policies, leading to higher testing volumes and market growth. The U.S. and Canada are the key players in this market, with the U.S. accounting for a substantial share of the global market. The increasing adoption of advanced cardiac biomarkers such as Troponins and BNP for early diagnosis and management of heart diseases further drives growth. North America’s strong focus on innovation and research in cardiovascular care is expected to sustain its leadership position in the market, with a growing shift towards personalized and point-of-care diagnostics.
• The Asia-Pacific (APAC) region is experiencing the fastest growth in this market. The rising burden of cardiovascular diseases, driven by lifestyle changes and aging populations, is the primary factor fueling this growth. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death in the Asia-Pacific region, particularly in countries like China and India, where population aging and urbanization are rapidly increasing. The growing healthcare expenditure, improvements in healthcare infrastructure, and rising awareness about early diagnosis are contributing to the increased adoption of cardiac biomarkers in the region. Additionally, the region is seeing a surge in point-of-care testing, as healthcare access improves. As the demand for accurate and rapid diagnostics rises, countries such as China, India, and Japan are expected to play a major role in driving the market forward in the coming years. With expanding healthcare capabilities and government initiatives to combat cardiovascular disease, the Asia-Pacific region is predicted to maintain its high growth trajectory.

Cardiac Biomarkers Market Competitive Overview

The global market is highly competitive, driven by the growing demand for accurate and timely diagnostics in the management of cardiovascular diseases. Key players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific, among others. These companies are focusing on product innovations, strategic partnerships, and acquisitions to expand their market presence. The increasing prevalence of cardiovascular diseases, with over 697,000 heart disease-related deaths reported in the U.S. by the Centers for Disease Control and Prevention (CDC), is fueling the need for more advanced and reliable cardiac biomarkers. Market leaders are investing in research and development to improve biomarker testing methods, enhance sensitivity and specificity, and reduce diagnostic times. Furthermore, there is a rising trend of point-of-care testing, which is attracting investments from major diagnostic companies. Emerging players are also entering the market, particularly in regions such as Asia-Pacific, where the demand for this market is growing rapidly due to the rising burden of cardiovascular diseases. With a strong emphasis on technological advancements and expanding healthcare infrastructure, the competitive landscape of the market is poised for continuous growth.

Leading Market Players in the Cardiac Biomarkers Market

• Abbott Laboratories: Abbott Laboratories is a leading player in the global market, offering a wide range of diagnostic tests and devices. The company’s innovation in cardiac biomarker diagnostics is highlighted by its high-sensitivity Troponin tests, which are widely used to diagnose myocardial infarction (MI). Abbott's diagnostics division is supported by a global presence, ensuring that advanced cardiac testing is available across multiple regions. The company continues to invest in research and development, driving innovations in point-of-care testing solutions. Abbott Laboratories is a key player in North America and is expanding its reach in emerging markets.
• Siemens Healthineers: Siemens Healthineers is renowned for its contributions to the healthcare sector, particularly in diagnostic imaging and laboratory diagnostics. Its cardiac biomarkers portfolio includes state-of-the-art Troponin and BNP tests, widely used in clinical settings to diagnose heart-related conditions. Siemens Healthineers has a strong focus on providing integrated solutions, combining laboratory diagnostics with advanced imaging technologies. The company's leadership in medical technology and diagnostics is reflected in its market presence, with an emphasis on enhancing diagnostic accuracy and efficiency. Siemens is particularly strong in Europe and North America and is expanding its operations in Asia-Pacific.
• Thermo Fisher Scientific Inc.: Thermo Fisher Scientific Inc. is a prominent global leader in laboratory equipment and diagnostic solutions, including cardiac biomarker assays. The company offers a range of diagnostic tools for myocardial infarction and heart failure, including highly sensitive Troponin and BNP assays. Thermo Fisher’s focus on precision medicine and its broad portfolio of diagnostic products make it a key player in this market. The company has a significant presence in both research and clinical diagnostics and continues to expand its offerings through strategic acquisitions and partnerships. Its advancements in biomarker testing technology further solidify its competitive position.

Top Strategies Followed by Players:

• Strategic Partnerships and Collaborations: Many key players in this market, including Abbott Laboratories and Siemens Healthineers, focus on strategic collaborations to enhance their product portfolios. For instance, Abbott has partnered with hospitals and healthcare providers to improve access to point-of-care diagnostic solutions. These partnerships enable companies to expand their geographical reach, enter new markets, and drive the adoption of advanced cardiac biomarker tests. Collaborations also foster innovation, as companies share expertise and resources to develop cutting-edge diagnostic technologies. These alliances play a critical role in improving product offerings and meeting the evolving demands of healthcare systems globally.
• Research and Development Investments: Continuous innovation through research and development is a key strategy employed by leaders like Thermo Fisher Scientific and Roche Diagnostics. These companies allocate substantial funds towards R&D to develop next-generation diagnostic tools, enhancing the accuracy, speed, and ease of cardiac biomarker testing. For instance, Roche has developed highly sensitive Troponin tests, enabling better diagnosis of heart conditions. These investments allow companies to maintain a competitive edge by introducing advanced technologies, improving diagnostic efficiency, and addressing the growing demand for personalized and precise healthcare solutions.
• Expanding Point-of-Care Testing Solutions: As the demand for rapid and accurate diagnostics grows, many companies, including Siemens Healthineers and Bio-Rad Laboratories, are focusing on expanding their point-of-care testing (POCT) offerings. POCT solutions provide faster results, reduce patient wait times, and increase diagnostic accuracy. Companies like Siemens Healthineers have advanced the development of portable diagnostic devices and systems that can be used in emergency settings, contributing to improved healthcare outcomes. The shift toward POCT is particularly significant in regions with limited access to traditional healthcare facilities, helping bridge gaps in healthcare accessibility.

List of Companies Profiled in the Report are:

• Abbott laboratories
• Siemens Healthcare
• Thermo Fisher Scientific Inc.
• Becton
• Dickinson And Co.
• Bio-Rad Laboratories
• Randox laboratories
• Alere Inc.
• Beckman Coulter
• BioMerieux
• Roche Diagnostics Corporation

Global Cardiac Biomarkers Market Report Scope and Key Segmentation

List of Segments Covered

This section of the Market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Myocardial Muscle Creatine Kinase (CK-MB)
• Troponins (T and I)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

By Application

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

By Location of Testing

• Point of Care Testing
• Laboratory Testing